Patients with advanced-stage leiomyosarcoma, a type of soft-tissue sarcoma that occurs predominantly in uterine locations, typically receive doxorubicin and have a median overall survival (OS) of ~20 months. Now, data from a randomized phase III trial demonstrate that adding trabectedin to doxorubicin significantly improves OS.

A total of 150 patients with previously untreated locally advanced or metastatic leiomyosarcoma were randomly assigned (1:1) to receive doxorubicin plus trabectedin (up to 6 cycles) followed by maintenance trabectedin, or doxorubicin (up to 6 cycles). Post-treatment surgical resection of residual disease was permitted for all patients. Progression-free survival (PFS) was the primary end point.

晚期平滑肌肉瘤是一种主要发生在子宫部位的软组织肉瘤，患者通常接受阿霉素治疗，中位总生存期 （OS） 为 ~20 个月。现在，来自随机 III 期试验的数据表明，在阿霉素中加入曲贝替定可显著改善 OS。

共有 150 例既往未经治疗的局部晚期或转移性平滑肌肉瘤患者被随机分配 （1：1） 接受阿霉素加曲贝替定（最多 6 个周期），然后接受维持曲贝替定或阿霉素（最多 6 个周期）。所有患者均允许治疗后手术切除残留病灶。无进展生存期 （PFS） 是主要终点。